Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Biostar initiates phase I/II trial of Norelin in prostate cancer patients and creates subsidiary

Feb. 19, 1999

Ontak available this month in U.S.

Feb. 16, 1999

Review supports hCG as a target for cancer immunotherapy

Feb. 15, 1999

Ligand purchases Marathon Biopharmaceuticals' assets

Feb. 15, 1999

PSP94 suppresses prostate cancer growth in mouse model

Feb. 12, 1999

Enrollment completed in Maxim's malginant melanoma phase III trial

Feb. 9, 1999

Ligand receives FDA approval for Ontak as CTCL treatment

Feb. 8, 1999

ImmunoGen and SB enter agreement for colorectal cancer treatment

Feb. 4, 1999

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Feb. 3, 1999

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...